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Identification and Characterization of
Tumor-Initiating Cells in Human Primary Cutaneous
Squamous Cell Carcinoma
Girish K. Patel1, Carole L. Yee1, Atsushi Terunuma1, William G. Telford2, Nga Voong2, Stuart H. Yuspa3
and Jonathan C. Vogel{,1
Primary human squamous cell carcinomas (SCCas) are heterogeneous invasive tumors with proliferating outer
layers and inner differentiating cell masses. To determine if tumor-initiating cells (TICs) are present in SCCas, we
utilized newly developed reliable in vitro and in vivo xenograft assays that propagate human SCCas, and
demonstrated that a small subset of SCCa cells (B1%) expressing Prominin-1 (CD133) in the outer layers of
SCCas were highly enriched for TICs (B1/400) compared with unsorted SCCa cells (TICsB1/106). Xenografts of
CD133þ SCCas recreated the original SCCa tumor histology and organizational hierarchy, whereas CD133
cells did not, and only CD133þ cells demonstrated the capacity for self-renewal in serial transplantation
studies. We present a model of human SCCas in which tumor projections expand with outer leading edges that
contain CD133þ TICs. Successful cancer treatment will likely require that the TICs identified in cancers be
targeted therapeutically. The demonstration that TICs are present in SCCas and are enriched in a CD133
expressing subpopulation has not been, to our knowledge, previously reported.
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INTRODUCTION
The molecular pathogenesis of human cutaneous squamous
cell carcinomas (SCCas) likely involves a number of different
genetic and epigenetic alterations (Boukamp, 2005) inclu-
ding frequent mutations in p53 and upregulation of Ras
activity. (Brash et al., 1991; Ziegler et al., 1994; Dajee et al.,
2003). Histologically, human SCCas are heterogenous tumors
that contain both proliferating and differentiating keratino-
cytes (Murphy et al., 1984; Watanabe et al., 1995) organized
in a hierarchy that recapitulates normal epidermal develop-
ment. As the cellular hierarchy of normal epidermis is
reconstituted by keratinocyte stem cells, it is possible that
human SCCas are also initiated by cancer stem cells or
tumor-initiating cells (TICs) that possess long-term proli-
ferative and self-renewal capacity and can reconstitute the
tumor hierarchy and cellular heterogeneity in SCCas (Dick,
2009). In tumors that lack a clear organizational hierarchy,
as a recent study suggests in the case of melanoma,
TICs may not be present in a distinct subpopulation or
may be present at very high frequencies (Eaves, 2008;
Quintana et al., 2008; Dick, 2009). The isolation and
characterization of potential TICs in cutaneous SCCas
would facilitate the elucidation of the fundamental changes
required to achieve both tumor formation and hierarchical
organization.
One approach to identify TIC-enriched subpopulations in
human SCCas could involve characterization of the anatomi-
cal heterogeneity of human SCCas using both biological
(differentiation) and cell surface markers that identify kerati-
nocyte stem cells in the hair follicle bulge region (CD200) and
other populations in other hair follicle regions and epidermis
(CD24, CD34, CD71, and CD146) (Ohyama et al., 2006).
Application of additional cell surface markers that identify
TICs in other epithelial human cancers, including CD44
(hyaluronan receptor) for breast cancer (Al-Hajj et al., 2003),
head and neck cancer (Prince et al., 2007), and colorectal
cancer (Dalerba et al., 2007), and CD133 (prominin-1) for
lung cancer (Eramo et al., 2008) and colon cancer (O’Brien
et al., 2007; Ricci-Vitiani et al., 2007; Shmelkov et al., 2008),
could then be added to narrow the search.
A sensitive reproducible in vivo orthotopic xenograft
mouse model is needed to demonstrate that TICs are present
in distinct subpopulations of human cutaneous SCCa cells.
In a companion paper, we describe a recently developed
model that is capable of initiating and maintaining the
heterogeneous SCCa hierarchy when isolated tumor cells are
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implanted into immunocompromised mice (Patel et al.,
2011). We now describe the isolation and characterization
of a small subpopulation of tumor cells that exhibit long-term
proliferative and self-renewal capacities and give rise to
more differentiated tumor cells. We propose that these cells
include SCCa TICs.
RESULTS
Primary human SCCas are heterogeneous with characteristic
patterns of epidermal proliferation and differentiation
Primary human cutaneous SCCas comprise multiple finger-like
tumor projections (Figure 1a) characterized by inner cell masses
of keratinocytes that do not proliferate and express involucrin
(Figure 1b and c; Supplementary Figure S1 online) and Ki-67þ
proliferating keratinocytes that are located on the outer edges
of tumor projections (Figure 1b and Supplementary Figure S1
online). These results suggest that human SCCa keratinocytes
differentiate after they leave the proliferating layer, similar to
normal epidermis (Murphy et al., 1984; Watanabe et al., 1995).
The presence of proliferating and differentiating keratinocytes
within primary human SCCas is consistent with an organiza-
tional hierarchy suggesting the presence of TICs that can
reconstitute and maintain human SCCas.
Defining distinct keratinocyte subsets in primary human SCCas
We utilized a panel of CD markers (CD24, CD34, CD71,
CD146, and CD200) that we had previously demonstrated
could distinguish distinct keratinocyte populations within
normal human hair follicles (Ohyama et al., 2006). CD71
(transferrin receptor), normally expressed by proliferating
outer root sheath keratinocytes of hair follicles, was only
expressed by proliferating outer cell layers of primary human
SCCas (Figure 1c and d; Supplementary Figure S2 online)
whereas CD24 and CD146 were each expressed exclusively
by differentiating keratinocytes in tumor inner cell masses
(Supplementary Figure S2 online). CD71 expression was
confirmed by FACS analysis and was consistently detected
in B8±6% (n¼ 9) of keratinocytes in cell suspensions
prepared from human SCCas (Supplementary Table S1
online). As human SCCas contained variable numbers of
inflammatory cells (mean 16±16%; n¼45; Supplementary
Tables S1 and S2 online), all FACS analyses included
monoclonal antibodies reactive with CD45, the common
leukocyte antigen, to identify these cells. CD34 was not
detected on human SCCa keratinocytes by immunohisto-
chemical analysis, but CD34 was identified on endothelial
cells in the SCCa stroma (Supplementary Figure S2 online).
Of interest, although we previously demonstrated that CD200
could identify human keratinocyte stem cells located in the
hair follicle bulge area, we did not detect CD200 expression
on keratinocytes in human SCCas, either by immunohisto-
chemical or FACS analysis (Supplementary Figure S2 online).
A subset of primary human SCCa keratinocytes
expresses CD133
CD44- and CD133-expressing TICs have been identified in
other cancers (Al-Hajj et al., 2003; Singh et al., 2004;
Dalerba et al., 2007; O’Brien et al., 2007; Prince et al., 2007;
Ricci-Vitiani et al., 2007; Yi et al., 2007; Eramo et al., 2008;
Shmelkov et al., 2008). Expression of CD44, used to enrich
TIC populations in breast, head and neck, pancreas, and
colorectal cancers (Al-Hajj et al., 2003; Dalerba et al., 2007;
Prince et al., 2007), was detected by immunofluorescence
(data not shown) and FACS exclusively on CD45þ non-
keratinocytes scattered throughout SCCa tumors (Figure 1d),
consistent with previous reports of absent or downregulated
CD44 expression on SCCa keratinocytes (Janes and Watt,
2006).
In contrast, primary human SCCa tumor sections labeled
for CD133 using antibody AC133 (epitope 1, glycosylation-
dependent) demonstrated basal layer cell surface expression
on relatively rare cells in proliferating CD71þ outer cell
layers (Figure 1e). CD133þ cells also expressed cytokeratin
14 but did not express CD31 (PECAM-1), thereby excluding
endothelial cells and identifying CD133þ cells as keratino-
cytes (Figure 1e and Supplementary Figure S3 online). FACS
analysis of 39 primary human SCCas demonstrated CD133þ
expression by 0.9±0.9% of SCCa cells (Figure 1d and f and
Supplementary Table S2 online). CD133þ SCCa keratino-
cytes were less heterogeneous when compared with equiva-
lent numbers of total primary human SCCa single cells with
regard to forward and side scatter (Supplementary Figure S4
online). Similar percentages of CD133þ CD45 cells were
present in different histologic grades of human SCCas by
FACS analysis (Figure 1f). Thus, CD133þ keratinocytes
comprised a relatively rare subset (B1%) of keratinocytes in
human SCCas and were located in the CD71þ outer
proliferating layers of SCCa tumor projections.
CD133þ human SCCa keratinocytes are enriched for
colony-forming cells in an in vitro assay for human SCCas
Primary human SCCa cells formed colonies when grown in
an adapted keratinocyte colony-forming assay that incorpo-
rates a NIH 3T3 feeder layer to support growth (Terunuma
et al., 2007). During culture, primary human SCCa cells
attached to NIH 3T3 cells in the feeder layers and not to
tissue culture plate surfaces. After 14 days in culture,
compact spheroidal colonies formed with 4100 cells
tethered to NIH 3T3 feeder cells (Figure 2a). In contrast,
normal human keratinocytes attached directly to tissue
culture plates and formed adherent monolayer colonies
(Terunuma et al., 2007) (Figure 2a). Increased numbers of
tethered sphere colonies formed when increased numbers of
SCCa tumor cells were cultured, demonstrating a dose-
response relationship (Figure 2b). The cultured tethered
spheres could also be serially passaged with B50 tethered
sphere colonies formed from an initial inoculum of 105
human SCCa cells. Also, when colonies identified by inverted
light microscopy were isolated using cloning cylinders
and then serially passaged, these resulted in equivalent
numbers of secondary colonies. Thus, the serial passage
studies demonstrated that only 1 to 2 colony-forming cells
were present on average in each tethered sphere. Impor-
tantly, these colonies contained tumor-derived keratinocytes
(Figure 2c). To confirm that these tethered sphere colonies
contained TICs, we also demonstrated that xenografts of
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Figure 1. Characterization of squamous cell carcinoma (SCCa) cellular subsets. (a) Schematic of a primary human SCCa and stained section.
Immunofluorescence of a SCCa tumor section labeled for (b) involucrin (green) and KI67 (purple) and (c) CD71 (green) and involucrin (red) and counterstained
with 4,6-diamidino-2-phenylindole (DAPI; blue). (d) FACS of primary human SCCas demonstrating cell surface marker expression together with isotype controls.
The red arrows indicate the CD45-negative tumor subpopulation of interest. Also shown is a FACS plot of CD133 and CD71 of a CD45 subpopulation.
(e) Immunofluorescence of an SCCa section labeled with CD133 (green), CD31 (red), keratin 14 (purple), and DAPI (blue). All scale bars¼100 mm. (f) CD133þ
CD45 percentages from total cell suspensions derived from 32 different histological grades of primary human SCCas.
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tethered sphere colonies recreated human SCCa tumors when
implanted in immunocompromised mice (Figure 2d).
To determine if TICs were enriched in the different SCCa
keratinocyte subsets, we screened sorted CD71þ and
CD133þ subpopulations for increased colony-forming
efficiency that might indicate enrichment of TICs. Highly
purified CD133þ and CD71þ human SCCa keratinocyte
subsets were isolated using magnetic bead (MACS) separation
or FACS sorting with 492% and 80% purity, respectively,
based on FACS analysis (Figure 2e). Cytospin analysis of the
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Figure 2. A CD133þ subpopulation in human squamous cell carcinomas (SCCas) with increased colony-forming efficiency in vitro. (a) A schematic showing
how normal keratinocytes form adherent colonies whereas SCCa tumor keratinocytes form spheriodal colonies in our in vitro assay. (b) The number of
colonies emerging from culture was dependent upon the number of cells plated. (c) Spheroids were then dissociated and after cytospin onto a slide, were labeled
with anti-pancytokeratin antibody, revealing the presence of keratinocytes within the spheroids. (d) These cell culture colonies formed tumors when xenografted
onto the backs of prepared athymic nude mice. (e) FACS for purity following magnetic bead separation (MACS) or FACS of CD133þ CD45 (red arrow)
primary human SCCa subpopulations (above panels). FACS for purity of the CD71þ CD45 (red arrow, left panel) and CD71 CD45 (red arrow, right panel)
sorted subpopulation (lower panels). (f, g) CD133 sorted cells demonstrate a statistically significant increased colony-forming efficiencies as compared with
equivalent numbers of unsorted and CD133 sorted cells (n¼ 6, the two experiments utilized different primary tumor samples; Po0.01). (h) Fold change in
colony-forming efficiencies for CD133þ , CD133, CD71þ , and CD71 subpopulations compared with unfractionated SCCa controls.
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CD133þ CD45 and CD133 CD45 purified subsets
demonstrated keratin expression in all CD133þ CD45
cells and most CD133 CD45 cells, confirming their
keratinocyte origin and purity (Supplementary Figure S5
online; n¼ 3), and also demonstrated the presence of the
same p53 mutation detected in the parental SCCa tumor
(Supplementary Figure S6 online). We determined that the
CD133þ CD45 SCCa keratinocytes were 47-fold more
efficient in colony formation than the CD133 CD45
sorted and unsorted total SCCa populations; Po0.01 (Figure
2f–h). In comparison, CD71þ CD45 SCCa cells were
B2-fold increased in spheroid colony-formation efficacy
compared with CD71 CD45 SCCa cells (Figure 2h).
As the differences in colony-formation efficiency might
reflect different proliferation rates for the sorted popula-
tions, cell cycle analysis showed that the CD133þ CD45
population was relatively quiescent compared with the
CD133 CD45 population (4.2% vs. 13.1% cells in G2/
M, respectively; Supplementary Figure S7 online), and thus
may represent a relatively quiescent population in the outer
proliferating SCCa layer. These results suggest that CD133þ
CD45 SCCa cells may be candidates for TICs.
TIC frequency in unsorted primary human SCCas
Successful and reproducible xenografts of human SCCa cell
suspensions onto immunocompromised mice were ultimately
achieved when large numbers of normal human fibroblasts
were used to ‘‘humanize’’ the xenograft recipient sites (Patel
et al., 2011). One million (106) primary normal human
fibroblasts were first suspended in Matrigel and implanted
subcutaneously with glass discs or Gelfoam dressing. After 14
days, SCCa xenograft cell suspensions were coinjected, along
with an additional 106 primary human normal fibroblasts
suspended in Matrigel into the xenograft sites (Figure 3a).
Using this approach, successful xenografts were assured
if X3 106 unsorted primary human SCCa cells were xeno-
grafted (28 successful xenograft tumors in 29 attempts) with
SCCa xenografts recapitulating the original SCCa histology.
The SCCa xenograft success rate demonstrated a clear dose
response (n¼ 82 xenografts), irrespective of the histological
grade, with no SCCa growth detectable for xenografts initiated
with o104 unsorted primary human SCCa cells (Figure 3b).
The estimated TIC frequency in unsorted SCCa cell sus-
pensions is 1 TIC in 1.4106 total unsorted SCCa cells
(0.00007%) (Supplementary Table S3 online), a TIC frequency
within the range previously reported for other human and
mouse carcinomas (Kennedy et al., 2007; Dick, 2009).
CD133þ primary human SCCa keratinocytes are enriched
for TICs
We assessed TIC enrichment in CD133þ and CD71þ SCCa
subpopulations because of their increased colony-forming
efficiency in vitro. For CD133þ CD45 sorted SCCa
keratinocytes from 28 different human SCCa specimens,
reproducible xenograft tumor growth (n¼ 41 xenografts) was
seen following implantation of 102–105 CD133þ CD45
keratinocytes. We estimate that TIC frequency is 1 TIC for
every 432 CD133þ CD45 SCCa keratinocytes (0.23%)
(Figure 4a and Supplementary Table S4 online). Importantly,
CD133þ CD45 SCCa xenografts, after 12 weeks of in vivo
growth, recreated the original primary human SCCa histology
(Supplementary Figure S8 online). The measured sizes of the
SCCa xenograft tumors correlated with the numbers of
CD133þ CD45 cells implanted (Supplementary Figure
S9 online). Of note, sorted CD133 CD45 SCCa keratino-
cytes did not yield SCCa xenograft tumors, even at numbers
sufficient for reproducible growth with unsorted cells. In all,
3106 CD133 CD45 cells were implanted from 20
different SCCas in 33 failed xenograft attempts (Figure 4a, first
column labeled CD133) without growth.
When various numbers of CD71þ CD45 SCCa kerati-
nocytes from 6 different SCCa specimens were xenografted
into 11 mice, only one SCCa tumor was detected in a mouse
that received 104 CD71þ CD45 keratinoctyes. No tumor
growth was observed when 105 CD71 CD45 SCCa
keratinocytes were xenografted (data not shown).
These results support our contention that TICs reside in the
outer layers of human SCCa tumor projections, and that TICs
can be greatly enriched using the cell surface marker CD133.
Sorted CD133þ CD45 keratinocytes were able to initiate
and recreate the histological heterogeneity of the original
tumors, whereas CD133 CD45 cells keratinocytes failed
to form tumors.
1+Hu Fb in
Matrigel
or
1+Hu SCCa
+1+ Hu Fb in
Matrigel
Remove
disc
Remove
tumor
84 Days
28/29
10/30
2/16
0/7
0
10
20
30
40
50
60
70
80
90
100
Fr
e
qu
en
cy
 o
f t
um
or
 fo
rm
a
tio
n 
(%
)
Transplanted tumor cells
14 Days
104 105 106 >3 × 106
Figure 3. Creation of a squamous cell carcinoma (SCCa) in vivo xenograft
model that can accurately recapitulate and propagate human SCCas.
(a) Successful generation of primary human SCCa xenografts from cell
suspensions required preimplantation of either a glass disc or a Gelfoam
dressing, combined with 106 primary human fibroblasts suspended in
Matrigel. After 14 days, SCCa tumor cells were combined with 106 primary
human fibroblasts in Matrigel and implanted into either the Gelfoam dressing
or the glass disc site. (b) Xenograft tumor growth (n¼82) following
implantation of different doses of total unfractionated SCCa cells.
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CD133þ human SCCa keratinocytes can self-renew
An essential property of TICs is their ability to self-renew
(in analogy to tissue stem cells) and to reconstitute SCCa
tumor heterogeneity during serial transfer into new recipient
mice. To test this, we serially transferred CD133þ SCCa
keratinoctyes derived from SCCa xenografts that were
initially prepared from eight different primary human SCCa
specimens (Figure 4b). When cell suspensions from the
second-generation SCCa xenografts were analyzed by flow
cytometry, B1% of the SCCa keratinocytes were CD133þ
(0.7±0.5%; n¼ 11; Supplementary Table S5 online), strik-
ingly similar to the percentage of CD133þ CD45 SCCa
keratinocytes in the original SCCa tumors. Different histolo-
gic grades of second-generation SCCa xenografts contained
comparable percentages of CD133þ CD45þ cells (Supple-
mentary Figure S10 online). When serially xenografted
into recipient mice, CD133þ SCCa keratinocytes obtained
from the initial SCCa xenografts produced secondary SCCa
xenograft tumors in a dose-dependent manner when 102 to
104 keratinocytes were implanted (Figure 4c) and had an
estimated TIC frequency of 1 TIC per 863 CD133þ
keratinocytes (Supplementary Table S6 online). Of the 14
secondary CD133þ xenografts from the 8 different primary
xenograft tumors, 10 demonstrated xenograft growth
(Figure 4c) and all that grew recapitulated original tumor
histologies (Supplementary Figure S8 online) and main-
tained the original patterns of differentiation (involucrin
expression), proliferation (Ki67 expression), and mutant p53
expression (Figure 5). CD133 keratinocytes from initial
xenografts again failed to initiate tumors when serially
implanted (Figure 4c, first column (CD133 cells)), thus
arguing against in vivo selection. In conclusion, primary
human SCCa contain TICs that reside in a small fraction
of CD133þ CD45 SCCa keratinocytes located in the
basal layer of the tumors and exhibit the stem cell property of
self-renewal.
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DISCUSSION
During human SCCa growth, tumor projections or ‘‘fingers’’
with proliferating outer layers of CD71þ keratinocytes invade
into the underlying dermis. These proliferating leading edges
surround central masses of more differentiated keratinocytes
that are CD24þ and CD146þ and that express the late
differentiation marker involucrin. Relatively rare small clusters
of CD133þ TIC keratinocytes are also present within the
proliferating CD71þ leading edge of SCCa tumor projections.
Our data provide strong experimental support for the
concept that TICs in human SCCas are present and enriched in
the CD133þ SCCa subpopulation: (1) the CD133þ subset
can accurately recreate the histology and organizational
hierarchy of the original SCCa tumor when transplanted in a
xenograft mouse model, whereas CD133 sorted SCCa cells
are consistently unable to recapitulate human SCCa; (2) the
CD133þ subpopulation is capable of efficient serial passage
whereas CD133 lack serial passage ability, demonstrating
self-renewal, high proliferative capacity, and long-term SCCa
reconstitution in the CD133þ subset; and (3) the percentage
of CD133þ cells in the original tumors and in serial passaged
xenografts was relatively invariant (B1%) and the TIC
frequency in these CD133þ subsets was also relatively
constant (B1/500). Additionally, within the CD133þ popu-
lation, subsets that are even more highly enriched for TICs
may be present and ultimately identifiable.
TICs have been proposed for a number of cancers (Dick,
2009). In the cancer stem cell model, tumor growth is
determined by a relatively small subpopulation of cells
that are solely responsible for initiating and maintaining
the tumor. In contrast to the classical model of tumor growth,
the cancer stem cell model predicts that the majority of the
tumors are composed of differentiated cells with limited
proliferative capacity that are unable to regenerate the tumor.
Consistent with this view, SCCas often contain differentiated
keratinocytes resulting in the ‘‘horny pearls’’ used by
pathologist to diagnose them. Similar to normal epidermal
maintenance, TICs are believed to maintain tumor growth by
virtue of their stem cell–like ability to self-renew and produce
differentiated progeny along predetermined lineages, and
their long-lived proliferative capacity. The cancer stem cell
model predicts that effective cancer therapies must target this
subpopulation of cells (TICs).
We do not know if TICs in human SCCas are derived from
normal keratinocyte stem cells or more committed progenitor
cells in human epidermis. CD133þ cells can be detected in
normal human epidermis by FACS analysis, but the function
of these cells in normal epidermis and whether these cells
have a functional relationship to the CD133þ keratino-
cytes that are enriched for TICs in human SCCas is uncertain.
Another unresolved question is what functional role, if any,
the prominin-1 (CD133) membrane glycoprotein has in TIC
biology (Bidlingmaier et al., 2008; Mizrak et al., 2008).
Although prominin-1 has previously been shown to interact
with membrane cholesterol microdomains and to be involved in
the processing and release of membrane particles from neural
progenitors and epithelial cells, a direct biological link to stem
cell behavior remains elusive (Dubreuil et al., 2007).
We hypothesize that human cutaneous SCCas are derived
from quiescent CD133þ malignant keratinocytes, the
so-called TICs, which differentiate and give rise to invasive
tumors. These CD133þ keratinocytes merit further study and
should help us understand the origin of TICs and the signaling
pathways that are important for their maintenance. Addition-
ally, it is possible that similar molecular mechanisms of
tumor initiation may exist for other epithelial SCCas, such as
head and neck cancers, and the selective targeting of their
TICs may be an effective therapeutic approach.
MATERIALS AND METHODS
Immunofluorescence
Immunofluorescence was performed using standard techniques with
the following primary antibodies: involucrin (Abcam, Cambridge,
MA; clone Sy5), Ki67 (Dako, Via Real Carpinteria, CA; clone mib-1),
CD71 (BD Pharmingen, San Diego, CA; M-A712), keratin 14 (gift
from Dr Julie Segre, Bethesda, MD), CD133 (Miltenyi-Biotec, Auburn,
CA; clone AC133), and CD31 (BD Pharmingen, clone WM59).
Immunohistochemistry
Immunohistochemistry was performed using standard antigen
retrieval techniques with the following primary antibodies: CD24,
CD34, CD71, CD146 (all from BD Pharmingen), CD200 (AbD
Serotec (Raleigh, NC), clone ox-104), pancytokeratin (Dako, clone
AE1/3), involucrin, Ki67, and p53 (BD Pharmingen, clone DO-7).
Cell preparation
As previously described (Patel et al., 2011), in brief, human SCCas
were obtained with the approval of the institutional review board.
Tumor tissue was mechanically dissociated, and then incubated for
2 hours with Dispase (BD Biosciences, San Diego, CA) and Ultrapure
Collagenase Type III (Sigma, St Louis, MO) at 37 1C. Supernatants
were removed after brief centrifugation, and the remaining tissue
was then incubated at 37 1C for 5minutes with trypsin 0.05% with
EDTA to create single-cell suspensions. Tissue remnants were
removed by filtration through a 40-mm cell strainer.
Flow cytometry
Samples were assessed using a FACSCalibur flow cytometer (BD
Biosciences) and mouse fluorochrome-conjugated IgG subtype
isotype controls (BD Pharmingen). Live cell gates were created
using 7-amino-actinomycin D (BD Pharmingen) to label dead cells.
Cells were labeled according to the manufacturer’s instructions with
fluorochrome-conjugated antibodies, CD44-PE (BD Pharmingen),
CD71-PE or APC (BD Pharmingen), CD45FITC (BD Pharmingen),
AC133-APC (Miltenyi-Biotec), and 293C3-APC (Miltenyi-Biotec).
Data were analyzed using Flowjo software (Tree Star, Ashland, OR).
Cell sorting
For magnetic separation, immediately after enzymatic dissociation,
cells were sorted using the Dead Cell Removal Microbead kit (Miltenyi-
Biotec) as per the manufacturer’s instructions. Viable cells were initially
negatively sorted using CD45 microbeads and then AC133 microbeads
were used to isolate CD133-positive and CD133-negative popula-
tions using a mini-MACS Separator (Miltenyi-Biotec) and MS columns
(Miltenyi-Biotec) for in vitro (n¼ 3) and in vivo (11 of 28 primary
CD133þ CD45 and CD133 CD45 xenografts) experiments.
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For flow sorting using a FACS Aria (Becton Dickinson, San Diego,
CA), cells were labeled with CD45FITC, AC133-APC or CD71-PE,
and the vital dye 7-amino-actinomycin D.
In vitro assay and tissue culture
Tumor samples were subjected to mechanical and enzymatic
dissociation as described above under Cell Preparation. Primary
human SCCa suspensions formed spheroidal colonies when grown
in an adapted keratinocyte colony-forming efficiency assay that
incorporates a NIH 3T3 feeder layer to support growth, and that we
had previously used to detect normal human keratinocyte stem cells.
Transplantation of human SCCa cell suspensions
As described previously (Patel et al., 2011), athymic nude homozygous
foxn1nu (Jackson Lab, Bar Harbor, ME), SCID-beige, and NOD-SCID
(Taconics, Rockville, MD) mice were maintained under conditions
approved by the animal care and use committee. Mice were
anesthetized and either Gelfoam dressings (Johnson & Johnson, New
Brunswick, NJ) or glass discs were implanted into dorsal subcutaneous
spaces together with 106 primary human fibroblasts suspended in
100ml of Matrigel (BD Biosciences) for single-cell suspension
experiments, and wounds were closed with surgical staples (Mikron,
Pittsburgh, PA). After 14 days, mice were anesthetized and glass discs
were removed, and then unsorted or magnetic or flow sorted CD133þ
and CD133 purified populations together with 106 primary human
fibroblasts resuspended in 100ml of Matrigel were injected into spaces
or alternatively into the Gelfoam dressings in situ. After 12 weeks, mice
were killed by CO2 inhalation and tumors were removed for analysis.
Statistical analysis
The frequencies of CD45þ , CD71þ , and CD133þ cells are
described as mean±SD. The differences between the mean number
of colonies (Supplementary Figure S2c,d online) and fold changes in
colony number over unsorted populations (Figure 2e) were
calculated using a paired t-test. Also, a t-test was used to compare
the colony-forming efficiencies of CD133þ versus CD133 and
CD71þ versus CD71 subpopulations. For in vivo limiting-dilution
assays, the frequencies of cancer-initiating cells were calculated
using L-Calc software (Stem Cell Technologies, Vancouver, BC,
Canada), with w2 analysis to determine internal consistency.
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